Published in Surg Oncol Clin N Am on April 01, 2008
An N-terminal truncated carboxypeptidase E splice isoform induces tumor growth and is a biomarker for predicting future metastasis in human cancers. J Clin Invest (2011) 1.02
Evaluation of miR-122-regulated suicide gene therapy for hepatocellular carcinoma in an orthotopic mouse model. Chin J Cancer Res (2013) 0.78
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
p53 mutations in human cancers. Science (1991) 31.96
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 22.46
Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med (1999) 17.03
Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer (2006) 10.05
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol (2006) 6.95
The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med (2003) 6.06
An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (1996) 5.97
Epidemiology of hepatocellular carcinoma. Clin Liver Dis (2005) 4.29
An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg (1999) 4.26
T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science (1995) 3.87
Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57
Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med (1995) 3.37
Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg (2001) 3.25
Hepatocellular carcinoma: the need for progress. J Clin Oncol (2005) 3.11
Alcohol and hepatocellular carcinoma. Gastroenterology (2004) 2.61
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol (2005) 2.56
Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res (2003) 2.12
New therapies for hepatocellular carcinoma. Oncogene (2006) 2.05
Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood (2001) 1.84
Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood (2001) 1.82
Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer (2006) 1.71
Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl (2004) 1.62
Antisense oligonucleotide-based therapeutics for cancer. Oncogene (2003) 1.54
Herpes simplex virus thymidine kinase-mediated suicide gene therapy for hepatocellular carcinoma using HIV-1-derived lentiviral vectors. J Hepatol (2004) 1.49
Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther (2007) 1.46
Gene therapy of liver tumors with human liver-specific nanoparticles. Cancer Gene Ther (2006) 1.46
Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol (2005) 1.45
Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology (2006) 1.40
Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther (2006) 1.39
Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br J Cancer (2004) 1.15
Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res (2005) 1.15
Hepatocellular carcinoma: overcoming challenges in disease management. Clin Gastroenterol Hepatol (2006) 1.13
ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer (2005) 1.12
Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio. J Transl Med (2007) 1.10
Hepatocellular carcinoma. Ann Oncol (2001) 1.03
Antitumor efficacy of regional oncolytic viral therapy for peritoneally disseminated cancer. J Mol Med (Berl) (2000) 1.03
Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology (2006) 1.00
Telomeres and telomerase. Keio J Med (2000) 0.97
p53 gene in treatment of hepatic carcinoma: status quo. World J Gastroenterol (2007) 0.95
Neoadjuvant and adjuvant therapy for operable hepatocellular carcinoma. Cochrane Database Syst Rev (2000) 0.91
Detection of adenovirus and initiation of apoptosis in hepatocellular carcinoma cells after Ad-p53 treatment. Hepatology (2000) 0.88
Emerging drugs for hepatocellular carcinoma. Expert Opin Emerg Drugs (2006) 0.88
Tissue-specific growth suppression and chemosensitivity promotion in human hepatocellular carcinoma cells by retroviral-mediated transfer of the wild-type p53 gene. Hepatology (1996) 0.87
Gene therapy strategies for hepatocellular carcinoma. J Biomed Sci (2006) 0.86
Gene therapy of liver cancer. World J Gastroenterol (2006) 0.86
Prolonged survival of mice with multiple liver metastases of human colon cancer by intravenous administration of replicable E1B-55K-deleted adenovirus with E1A expressed by CEA promoter. Mol Ther (2004) 0.85
Reversing hepatocellular carcinoma progression by using networked biological therapies. Clin Cancer Res (2007) 0.85
Oncolytic herpes viral therapy is effective in the treatment of hepatocellular carcinoma cell lines. J Gastrointest Surg (2006) 0.85
IGF-I: from diagnostic to triple-helix gene therapy of solid tumors. Acta Biochim Pol (2002) 0.82
Advancements in hepatocellular carcinoma. Curr Opin Gastroenterol (2007) 0.81
Enhanced antitumor effects of a bicistronic adenovirus vector expressing both herpes simplex virus thymidine kinase and monocyte chemoattractant protein-1 against hepatocellular carcinoma. Cancer Gene Ther (2003) 0.80
Radioembolization with Yttrium-90 microspheres: review of an emerging treatment for liver tumors. Future Oncol (2007) 0.79
Practical considerations in the treatment of hepatocellular carcinoma. Drugs (1998) 0.78
Liver-directed therapies for hepatocellular carcinoma. J Natl Compr Canc Netw (2006) 0.77
Retrovirus-mediated herpes simplex virus thymidine kinase gene therapy approach for hepatocellular carcinoma. Cell Res (1999) 0.76
Oncolytic recombinant herpes simplex virus for treatment of orthotopic liver tumors in nude mice. Int J Oncol (2006) 0.76
Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg (2002) 8.30
The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33
Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol (2007) 4.95
Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire. J Clin Oncol (2002) 4.16
Pasireotide for postoperative pancreatic fistula. N Engl J Med (2014) 3.84
A selective approach to the resection of cystic lesions of the pancreas: results from 539 consecutive patients. Ann Surg (2006) 3.34
Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg (2008) 3.16
Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Ann Surg (2003) 3.14
Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer (2003) 2.96
Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol (2006) 2.66
American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol (2009) 2.52
Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol (2010) 2.51
Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2cm or smaller. J Natl Cancer Inst (2013) 2.45
Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma. Cancer Biol Ther (2006) 2.45
Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg (2003) 2.36
Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. J Clin Oncol (2003) 2.36
Operative drainage following pancreatic resection: analysis of 1122 patients resected over 5 years at a single institution. Ann Surg (2013) 2.29
Analysis of the extent of resection for adenocarcinoma of the gallbladder. Ann Surg Oncol (2008) 2.28
Predicting the risk of perioperative transfusion for patients undergoing elective hepatectomy. Ann Surg (2009) 2.27
The impact of margins on outcome after hepatic resection for colorectal metastasis. Ann Surg (2007) 2.23
Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg (2007) 2.22
The use of fresh frozen plasma after major hepatic resection for colorectal metastasis: is there a standard for transfusion? J Am Coll Surg (2003) 2.20
Combined blunt-clamp dissection and LigaSure ligation for hepatic parenchyma dissection: postcoagulation technique. J Am Coll Surg (2009) 2.19
Diagnosis, management, and outcomes of 115 patients with hepatic hemangioma. J Am Coll Surg (2003) 2.09
Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J Am Coll Surg (2003) 2.06
Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg (2003) 2.05
Prognostic immune markers in non-small cell lung cancer. Clin Cancer Res (2011) 2.03
(124)I-huA33 antibody PET of colorectal cancer. J Nucl Med (2011) 2.01
Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg (2010) 1.98
Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg (2003) 1.97
Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma. Ann Surg (2009) 1.94
Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas? Hepatology (2012) 1.94
Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J Gastrointest Surg (2007) 1.86
Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg (2008) 1.85
Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer (2002) 1.85
Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. J Clin Oncol (2010) 1.80
Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg (2003) 1.79
A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer. Ann Surg (2008) 1.76
Staging laparoscopy in patients with extrahepatic biliary carcinoma. Analysis of 100 patients. Ann Surg (2002) 1.75
Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Ann Surg Oncol (2011) 1.75
Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol (2005) 1.73
Ablation of perivascular hepatic malignant tumors with irreversible electroporation. J Am Coll Surg (2012) 1.71
Nectin-1 expression by squamous cell carcinoma is a predictor of herpes oncolytic sensitivity. Mol Ther (2007) 1.71
Laparoscopic adrenalectomy for isolated adrenal metastasis. Ann Surg Oncol (2007) 1.71
Overexpression of E2F-1 in lung and liver metastases of human colon cancer is associated with gene amplification. Cancer Biol Ther (2004) 1.67
Hepatocellular carcinoma: current surgical management. Gastroenterology (2004) 1.66
Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer (2006) 1.66
Management of primary liver sarcomas. Cancer (2007) 1.65
Caudate hepatectomy for cancer: a single institution experience with 150 patients. J Am Coll Surg (2005) 1.64
Yttrium 90 microsphere selective internal radiation treatment of hepatic colorectal metastases. Arch Surg (2007) 1.63
Cervical pharyngostomy: an old technique revisited. Ann Surg (2008) 1.63
Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? Oncology (2011) 1.61
Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol (2006) 1.60
Partial hepatectomy for metastases from noncolorectal, nonneuroendocrine carcinoma. Ann Surg (2005) 1.60
Contemporary experience with postpancreatectomy hemorrhage: results of 1,122 patients resected between 2006 and 2011. J Am Coll Surg (2012) 1.58
Long-term outcomes following tumor ablation for treatment of bilateral colorectal liver metastases. JAMA Surg (2013) 1.58
Major hepatectomy with simultaneous pancreatectomy for advanced hepatobiliary cancer. J Am Coll Surg (2004) 1.58
Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Ann Surg (2011) 1.57
Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus. Surgery (2007) 1.54
Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68. Mol Cancer Ther (2009) 1.54
Gene therapy for rare diseases: summary of a National Institutes of Health workshop, September 13, 2012. Hum Gene Ther (2013) 1.54
Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma. Hum Gene Ther (2008) 1.53
Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg (2007) 1.52
Simple measurement of intra-abdominal fat for abdominal surgery outcome prediction. Arch Surg (2010) 1.52
18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg (2007) 1.51
Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. J Clin Oncol (2012) 1.50
Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery (2008) 1.50
Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol (2009) 1.50
Current management of pyogenic liver abscess: surgery is now second-line treatment. J Am Coll Surg (2010) 1.49
Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann Surg (2005) 1.49
Perihepatic lymph node micrometastases impact outcome after partial hepatectomy for colorectal metastases. Ann Surg Oncol (2008) 1.48
Preoperative predictors for complications after pancreaticoduodenectomy: impact of BMI and body fat distribution. J Gastrointest Surg (2007) 1.47
Laparoscopic distal pancreatectomy: evolution of a technique at a single institution. J Am Coll Surg (2010) 1.46
Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma. Ann Surg (2010) 1.43
Changes in the management of benign liver tumours: an analysis of 285 patients. HPB (Oxford) (2012) 1.42
Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg (2002) 1.42
Safety and efficacy of preoperative portal vein embolization with polyvinyl alcohol in 58 patients with liver metastases. AJR Am J Roentgenol (2005) 1.42
Cystic lesions of the pancreas: changes in the presentation and management of 1,424 patients at a single institution over a 15-year time period. J Am Coll Surg (2011) 1.41
Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther (2006) 1.39
A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. Mod Pathol (2012) 1.39
Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J Am Coll Surg (2007) 1.39
Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancer. Ann Surg (2008) 1.39
Paracrine regulation of pancreatic cancer cell invasion by peripheral nerves. J Natl Cancer Inst (2010) 1.36
Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Ther (2002) 1.36
Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo. J Clin Endocrinol Metab (2008) 1.35
Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann Surg (2003) 1.35
Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol (2008) 1.33
Solid pseudopapillary tumors of the pancreas. Clinical features, surgical outcomes, and long-term survival in 45 consecutive patients from a single center. J Gastrointest Surg (2010) 1.33
Gallbladder cancer: differences in presentation, surgical treatment, and survival in patients treated at centers in three countries. J Am Coll Surg (2010) 1.31
Fate of the remnant pancreas after resection of noninvasive intraductal papillary mucinous neoplasm. J Am Coll Surg (2007) 1.30
Current utility of staging laparoscopy for pancreatic and peripancreatic neoplasms. J Am Coll Surg (2007) 1.29
Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease. Am J Surg Pathol (2014) 1.29
Local surgical, ablative, and radiation treatment of metastases. CA Cancer J Clin (2009) 1.28
Effect on outcome of recurrence patterns after hepatectomy for colorectal metastases. Ann Surg Oncol (2010) 1.27
Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases. Hum Gene Ther (2002) 1.26
Outcome of partial hepatectomy for large (> 10 cm) hepatocellular carcinoma. Cancer (2005) 1.26
Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma. J Thorac Oncol (2009) 1.25